ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth

Oncogene

Volumn 35, Issue 12, 2016, Pages 1554-1564

  Humtsoe, J O ^a   Pham, E ^a   Louie, R J ^b   Chan, D A ^b   Kramer, R H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; HEREGULIN BETA 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN;

ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL DENSITY; CELL GROWTH; CELL HYPOXIA; CELL ORGANELLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; CELL DIVISION; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, ERBB-3; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84930999439     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.220     Document Type: Article

References (59)

1. Rogers SJ, Harrington KJ, Rhys-Evans P, OC P, Eccles SA. Biological significance of c-ErbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005; 24: 47-69.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature Rev Cancer 2011; 11: 9-22.
3. Roskoski R Jr. The ErbB/HER family of protein-Tyrosine kinases and cancer. Pharmacol Res 2014; 79: 34-74.
4. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-1354.
5. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007; 29: 655-664.
6. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, et al. Strong correlation between c-ErbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997; 3: 3-9.
7. Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012; 48: 1085-1089.
8. Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-And ErbB family-Targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev 2014; 40: 567-577.
9. Funayama T, Nakanishi T, Takahashi K, Taniguchi S, Takigawa M, Matsumura T. Overexpression of c-ErbB-3 in various stages of human squamous cell carcinomas. Oncology 1998; 55: 161-167.
10. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008; 15: 413-448.
11. Del Sordo R, Angiero F, Bellezza G, Cavaliere A, Mameli MG, Stefani M, et al. HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance. J Oral Pathol Med 39: 79-86.
12. Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T. Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett 1995; 95: 79-83.
13. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5: 4164-4174.
14. Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol Endocr Metab Agents Med Chem 2011; 11: 131-149.
15. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010; 21: 944-950.
16. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011; 20: 158-172.
17. Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One 2013; 8: e56765.
18. Abbott A. Cell culture: biology's new dimension. Nature 2003; 424: 870-872.
19. Page H, Flood P, Reynaud EG. Three-Dimensional tissue cultures: current trends and beyond. Cell Tissue Res 2013; 352: 123-131.
20. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
21. Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Crit Rev Oncol Hematol 2000; 36: 61-74.
22. Santini MT, Rainaldi G, Indovina PL. Apoptosis, cell adhesion and the extracellular matrix in the three-Dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol 2000; 36: 75-87.
23. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-Tumor therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 2007; 83: 849-871.
24. Breslin S, O'Driscoll L. Three-Dimensional cell culture: the missing link in drug discovery. Drug Discov Today 2013; 18: 240-249.
25. Humtsoe JO, Koya E, Pham E, Aramoto T, Zuo J, Ishikawa T, et al. Transcriptional profiling identifies upregulated genes following induction of epithelialmesenchymal transition in squamous carcinoma cells. Exp Cell Res 2012; 318: 379-390.
26. Ziober BL, Silverman Jr. S.S., Kramer RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 2001; 12: 499-510.
27. Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 29: 5500-5510.
28. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768-772.
29. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-Derived cell recruitment. Cancer Cell 2009; 15: 527-538.
30. Zou Y, Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Guan X, et al. The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids. J Radiat Res 2010; 51: 47-55.
31. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
32. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
33. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28: 461-468.
34. Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schafer KL, et al. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One 2013; 8: e59689.
35. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ, et al. Trastuzumab-induced HER reprogramming in resistant breast carcinoma cells. Cancer Res 2009; 69: 2191-2194.
36. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
37. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010; 70: 1989-1999.
38. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011; 108: 5021-5026.
39. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010; 107: 7692-7697.
40. Dubessy C, Merlin JM, Marchal C, Guillemin F. Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol 2000; 36: 179-192.
41. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-214.
42. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett 2011; 313: 1-8.
43. Paatero I, Seagroves TN, Vaparanta K, Han W, Jones FE, Johnson RS, et al. Hypoxia-inducible factor-1alpha induces ErbB4 signaling in the differentiating mammary gland. J Biol Chem 2014; 289: 22459-22469.
44. Zhu CH, Huang Y, Oberley LW, Domann FE. A family of AP-2 proteins downregulate manganese superoxide dismutase expression. J Biol Chem 2001; 276: 14407-14413.
45. Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 2010; 29: 5500-5510.
46. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486.
47. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-2200.
48. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep 2012; 13: 1116-1122.
49. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-Driven tumour cells. Biochem J 2012; 447: 417-425.
50. Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK, et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 2013; 123: 2155-2168.
51. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37: 535-540.
52. Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets 2013; 13: 245-251.
53. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007; 67: 10823-10830.
54. Sasabe E, Yang Z, Ohno S, Yamamoto T. Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. Free Radic Biol Med 2010; 48: 1321-1329.
55. Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 2011; 9: 126.
56. Matsumoto K, Horikoshi M, Rikimaru K, Enomoto S. A study of an in vitro model for invasion of oral squamous cell carcinoma. J Oral Pathol Med 1989; 18: 498-501.
57. Chen Q, Lipkina G, Song Q, Kramer RH. Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem Biophys Res Commun 2004; 315: 850-856.
58. Zuo J, Ishikawa T, Boutros S, Xiao Z, Humtsoe JO, Kramer RH. Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Mol Cancer Res 2010; 8: 170-182.
59. Humtsoe JO, Kramer RH. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene 2010; 29: 1214-1226.